The Pioneer platform: A novel approach for selection of selective anti-cancer cytotoxic activity in bacteria through co-culturing with engineered human cells

Most of the small-molecule drugs approved for the treatment of cancer over the past 40 years are based on natural compounds. Bacteria provide an extensive reservoir for the development of further anti-cancer therapeutics to meet the challenges posed by the diversity of these malignant diseases. While identifying cytotoxic compounds is often easy, achieving selective targeting of cancer cells is challenging. Here we describe a novel experimental approach (the Pioneer platform) for the identification and development of ‘pioneering’ bacterial variants that either show or are conduced to exhibit selective contact-independent anti-cancer cytotoxic activities. We engineered human cancer cells to secrete Colicin M that repress the growth of the bacterium Escherichia coli, while immortalised non-transformed cells were engineered to express Chloramphenicol Acetyltransferase capable of relieving the bacteriostatic effect of Chloramphenicol. Through co-culturing of E. coli with these two engineered human cell lines, we show bacterial outgrowth of DH5α E. coli is constrained by the combination of negative and positive selection pressures. This result supports the potential for this approach to screen or adaptively evolve ‘pioneering’ bacterial variants that can selectively eliminate the cancer cell population. Overall, the Pioneer platform demonstrates potential utility for drug discovery through multi-partner experimental evolution.

[1]  A. Jemal,et al.  Cancer statistics, 2022 , 2022, CA: a cancer journal for clinicians.

[2]  G. Sethi,et al.  Bacteria as a treasure house of secondary metabolites with anticancer potential. , 2021, Seminars in cancer biology.

[3]  David J Newman,et al.  Natural Products as Sources of New Drugs over the Nearly Four Decades from 01/1981 to 09/2019. , 2020, Journal of natural products.

[4]  G. Lippi,et al.  Current Cancer Epidemiology , 2019, Journal of epidemiology and global health.

[5]  Adam M. Feist,et al.  The emergence of adaptive laboratory evolution as an efficient tool for biological discovery and industrial biotechnology. , 2019, Metabolic engineering.

[6]  Zakary S. Singer,et al.  Rapid screening of engineered microbial therapies in a 3D multicellular model , 2018, Proceedings of the National Academy of Sciences.

[7]  A. Mankin,et al.  Binding and Action of Amino Acid Analogs of Chloramphenicol upon the Bacterial Ribosome. , 2018, Journal of molecular biology.

[8]  Ruth Hershberg,et al.  Rapid Genetic Adaptation during the First Four Months of Survival under Resource Exhaustion , 2017, Molecular biology and evolution.

[9]  K. Kannan,et al.  Context-specific inhibition of translation by ribosomal antibiotics targeting the peptidyl transferase center , 2016, Proceedings of the National Academy of Sciences.

[10]  R. Winn,et al.  The soft agar colony formation assay. , 2014, Journal of visualized experiments : JoVE.

[11]  Z. Brentzel,et al.  Identification of Staphylococcus aureus α‐hemolysin as a protein drug that is secreted by anticancer bacteria and rapidly kills cancer cells , 2014, Biotechnology and bioengineering.

[12]  R. Lothe,et al.  Epigenetic and genetic features of 24 colon cancer cell lines , 2013, Oncogenesis.

[13]  Herman van Tilbeurgh,et al.  Characterization of colicin M and its orthologs targeting bacterial cell wall peptidoglycan biosynthesis. , 2012, Microbial drug resistance.

[14]  Suzie K. Hight,et al.  Immortalized epithelial cells derived from human colon biopsies express stem cell markers and differentiate in vitro. , 2010, Gastroenterology.

[15]  C. Beattie,et al.  Noncationic peptides obtained from azurin preferentially enter cancer cells. , 2009, Cancer research.

[16]  D. Mengin-Lecreulx,et al.  Colicin M Exerts Its Bacteriolytic Effect via Enzymatic Degradation of Undecaprenyl Phosphate-linked Peptidoglycan Precursors* , 2006, Journal of Biological Chemistry.

[17]  A. Chakrabarty,et al.  Internalization of bacterial redox protein azurin in mammalian cells: entry domain and specificity , 2005, Cellular microbiology.

[18]  A. Chakrabarty,et al.  Apoptosis or growth arrest: Modulation of tumor suppressor p53's specificity by bacterial redox protein azurin. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[19]  D. Majumdar,et al.  Bacterial redox protein azurin, tumor suppressor protein p53, and regression of cancer , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[20]  I. Chopra,et al.  Response of Escherichia coli hypermutators to selection pressure with antimicrobial agents from different classes. , 2002, The Journal of antimicrobial chemotherapy.

[21]  V. Braun,et al.  Ton-dependent colicins and microcins: modular design and evolution. , 2002, Biochimie.

[22]  K. Igarashi,et al.  Secretion of human EGF and IgE in mammalian cells by recombinant DNA techniques; use of a IL-2 leader sequence. , 1988, Cell structure and function.

[23]  H. Noller,et al.  Chloramphenicol, erythromycin, carbomycin and vernamycin B protect overlapping sites in the peptidyl transferase region of 23S ribosomal RNA. , 1987, Biochimie.

[24]  V. Braun,et al.  Colicin M is an inhibitor of murein biosynthesis , 1982, Journal of bacteriology.

[25]  D. Dexter,et al.  Heterogeneity of cancer cells from a single human colon carcinoma. , 1981, The American journal of medicine.

[26]  B. S. Hartley,et al.  Primary structure of a chloramphenicol acetyltransferase specified by R plasmids , 1979, Nature.

[27]  J. Rahal,et al.  Bactericidal and Bacteriostatic Action of Chloramphenicol Against Meningeal Pathogens , 1979, Antimicrobial Agents and Chemotherapy.

[28]  V. Braun,et al.  A common receptor protein for phage T5 and colicin M in the outer membrane of Escherichia coli B. , 1973, Biochimica et biophysica acta.

[29]  János Bérdy,et al.  Bioactive microbial metabolites. , 2005, The Journal of antibiotics.

[30]  W. V. Shaw Chloramphenicol acetyltransferase: enzymology and molecular biology. , 1983, CRC critical reviews in biochemistry.